Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide and how well it
works in treating older patients with acute myeloid leukemia (AML) who have undergone stem
cell transplant. Biological therapies, such as lenalidomide, may stimulate the immune system
in different ways and stop cancer cells from growing.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University